Updates are available Erratum dated 2017-02-01

Article History

Received: 19 May 2015

Accepted: 3 November 2016

First Online: 5 December 2016

Change Date: 19 December 2016

Change Type: Erratum

Change Details: In the version of this article initially published online, the abstract contained two typos reading, “Like to other neuropsychiatric disorders,…” and “transcranial-magnetic-stimulation therapy…” . These errors have been corrected in the print, PDF and HTML versions of this article.

Competing interests

: C.L. and A.T.D. have no competing interests. A.E. has received a research grant from Brain Resource. A.F.S. has served as a consultant to BrainCells, CeNeRx, BioPharma, CNS Response, Corcept Therapeutics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, InnoPharma, Lundbeck, Merck, Neuronetics, Novartis, Pathway Diagnostics, Pfizer, PharmaNeuroBoost, Quintiles, Sanofi, Synosis, Takeda, and Xytis; has equity in Amnestix, BrainCells, CeNeRx, Corcept Therapeutics, Forest Laboratories, Merck, Neurocrine Biosciences, Pfizer, PharmaNeuroBoost, Somaxon Pharmaceuticals and Synosis; has pharmacogenetic-use patents on the prediction of antidepressant response; and has received speaking fees from GlaxoSmithKline and Roche. G.S.A. has received grant support from Forest Pharmaceuticals; has consulted for Hoffman–LaRoche, Lilly, Pfizer and Otsuka; and has served at the speakers′ bureaus of AstraZeneca, Avanir, Forest, Merck, Novartis and Sunovion. M.J.D. has received research grants from Neuronetics. All other authors report no biomedical financial interests or potential conflicts of interest.